secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001628280-24-022186
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024
--------------------------------------------------------------------------------

- Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.
- Revenue fell to $0.5M from $158M, driven by termination of Biogen/Novartis collaborations.
- Cash $54.4M at March 31 (down from $81M); raised ~$24M gross via direct offering.
- Pfizer expects BLA/MAA submission for hemophilia A gene therapy in early 2025 if mid-2024 pivotal readout positive.
- Fabry gene therapy STAAR study fully dosed; seeking collaboration partner before registrational trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024022186/0001628280-24-022186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024022186/sgmo-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-022186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer